Back to search
FDAFDA · Food and drugs·Recall number D-0391-2025

Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.

Published May 7, 2025 · Recall initiated: April 18, 2025

Summary

FDA records drug Class II recall D-0391-2025, published May 7, 2025 and initiated April 18, 2025. Recalling firm: Preferred Pharmaceuticals, Inc.; Status: Ongoing; Reported quantity: 1190 Bottles; Lot: Lot #: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, L2324L, Exp: 7/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc.
Distributor
Nationwide in the US
Lot
Lot #: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, L2324L, Exp: 7/31/2026.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03. recalled?

Yes. FDA published recall D-0391-2025 on May 7, 2025. Reported hazard: cGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter